Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026
Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood.
Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> -<br />
Size, Share, Outlook, and <strong>Opportunity</strong><br />
<strong>Analysis</strong>, <strong>2018</strong> - <strong>2026</strong><br />
<strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong>, by Product Type (Calcium Carbonate, Calcium<br />
Acetate, Calcium Acetate/Magnesium Carbonate, Aluminum Hydroxide, Sevelamer<br />
Hydrochloride, Sevelamer Carbonate, Bixalomer, Lanthanum Carbonate,<br />
Sucroferric Oxyhydroxide, and Ferric Citrate), by Dosage Form (Tablet, Capsule,<br />
and Solution/Suspension), by Distribution Channel (Hospital Pharmacies, Retail<br />
Pharmacies, and Online Pharmacies) and by Region (North America, Latin<br />
America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and<br />
<strong>Opportunity</strong> <strong>Analysis</strong>, <strong>2018</strong> - <strong>2026</strong><br />
<strong>Hyperphosphatemia</strong> is a condition caused due to high level of phosphate or phosphorous in the<br />
blood. Phosphate is a chemical found in body and contain mineral called phosphorous.<br />
Phosphorus mineral is very important for the development of teeth and bones and also convert<br />
food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in<br />
very smaller amounts in the blood. Kidney functions for the management of phosphate level in<br />
the body. However, various complications/diseases results into impairment of kidney, which leads<br />
to chronically high level of phosphate in blood.<br />
<strong>Hyperphosphatemia</strong> is very common in people with chronic kidney disease more often in people<br />
with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes<br />
diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone<br />
levels.<br />
Request Sample Copy of this Business Report @<br />
https://www.coherentmarketinsights.com/insight/request-sample/1315<br />
For instance, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules<br />
86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease<br />
in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission<br />
for new drug Fexeric (R) (ferric citrate coordination complex), indicated for the treatment of<br />
hyperphosphatemia in adults with chronic kidney disease. In 2014, Keryx Biopharmaceuticals,<br />
Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly<br />
known as Zerenex), a new, oral iron-based treatment for dialysis patients with
hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia<br />
(ferric citrate) tablets. Auryxia is an absorbable iron-based phosphate binder indicated for the<br />
treatment of hyperphosphatemia in chronic kidney disease<br />
Strategic merger and acquisition by key players in the market is also expected to create a<br />
lucrative environment for the hyperphosphatemia drugs market growth. For instance, in 2013,<br />
OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO<br />
Health, Inc. has expanded its portfolio with Cytochroma Inc.’s Alpharen, a non-absorbed<br />
phosphate binder to treat hyperphosphatemia in dialysis patients.<br />
Furthermore, Asia Pacific hyperphosphatemia drugs market is expected to witness significant<br />
growth in near future owing to increasing approval of novel hyperphosphatemia treatment drug<br />
in key regions such as China, and Japan. For instance, in 2014, Japan Tobacco Inc. and its<br />
subsidiary Torii Pharmaceutical Co., Ltd. received manufacturing and marketing approval of Riona<br />
Tablets 250 mg from Japanese Ministry of Health, Labor and Welfare. Riona tablet is indicated for<br />
treatment of hyperphosphatemia, it is a new phosphate binder containing ferric citrate hydrate<br />
as the active pharmaceutical ingredient.<br />
Browse More About the Keyword <strong>Market</strong> Study @<br />
https://www.coherentmarketinsights.com/ongoing-insight/hyperphosphatemia-drugs-market-<br />
1976<br />
Report includes chapters which deeply display the following deliverable about industry:<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Research Objective and Assumption<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Purview - Report Description, Executive Summary, and Coherent<br />
<strong>Opportunity</strong> Map (COM)<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Dynamics, Regulations, and Trends <strong>Analysis</strong> - <strong>Market</strong> Dynamics,<br />
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value<br />
Chain <strong>Analysis</strong>, Porter’s <strong>Analysis</strong>, and PEST <strong>Analysis</strong><br />
• Global <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong>, By Regions<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Competition by Manufacturers including Production, Share,<br />
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Manufacturers Profiles/<strong>Analysis</strong> including Company Basic<br />
Information, Manufacturing Base and Its Competitors.<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Manufacturing Cost <strong>Analysis</strong> including Key Raw Materials and<br />
Key Suppliers of Raw Materials.<br />
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials<br />
Sourcing and Downstream Buyers<br />
• <strong>Market</strong>ing Strategy <strong>Analysis</strong>, Distributors/Traders including <strong>Market</strong>ing Channel, <strong>Market</strong> Positioning<br />
and Distributors/Traders List.<br />
• <strong>Market</strong> Effect Factors <strong>Analysis</strong> including Technology Progress/Risk, Consumer Needs/Customer<br />
Preference Change and Economic/Political Environmental Change.<br />
• <strong>Hyperphosphatemia</strong> <strong>Drugs</strong> <strong>Market</strong> Forecast including Production, Consumption, Import and Export<br />
Forecast by Type, Applications and Region.
• Research Findings and Conclusion<br />
Table of Contents of Keyword <strong>Market</strong> Report:<br />
1. Research Objective and assumption<br />
2. <strong>Market</strong> Purview<br />
3. <strong>Market</strong> Dynamics, Regulations, and Trends <strong>Analysis</strong><br />
4. Keyword <strong>Market</strong>, By Advanced Water Meters, 2017 - 2025 (USD Million)<br />
5. Keyword <strong>Market</strong>, By Service, 2017 - 2025 (USD Million)<br />
6. Keyword <strong>Market</strong>, By Solution, 2017 - 2025 (USD Million)<br />
7. Keyword <strong>Market</strong>, By Regions, 2017 - 2025 (USD Million)<br />
8. Competitive Landscape<br />
Ask for Discount before Buying @<br />
https://www.coherentmarketinsights.com/insight/request-discount/1976<br />
About Coherent <strong>Market</strong> Insights:<br />
Coherent <strong>Market</strong> Insights is a prominent market research and consulting firm offering action-ready<br />
syndicated research reports, custom market analysis, consulting services, and competitive analysis<br />
through various recommendations related to emerging market trends, technologies, and potential<br />
absolute dollar opportunity.<br />
Contact Us:<br />
Mr. Shah<br />
Coherent <strong>Market</strong> Insights<br />
1001 4th Ave,<br />
#3200<br />
Seattle, WA 98154<br />
Tel: +1-206-701-6702<br />
Email: sales@coherentmarketinsights.com
Change language